Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shantha Biotech Of India Entertains GSK As New Suitor

This article was originally published in PharmAsia News

Executive Summary

India's Shantha Biotech has attracted another suitor, this time GlaxoSmithKline. GSK seeks a 51 percent stake in Shantha, whose recent negotiations with Sanofi Aventis for a similar deal fell apart. The shares GSK seeks are some of those owned by Merieux Alliance of France. Merieux bought a 60 percent stake in Shantha in 2006 and added another 20 percent recently. GSK seeks Shantha's vaccine business. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071777

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel